Max Scheder Bieschin Net Worth

The estimated Net Worth of Max Scheder Bieschin is at least $36.6 Thousand dollars as of 7 September 2017. Max Bieschin owns over 10,000 units of Ekso Bionics Inc stock worth over $36,625 and over the last 9 years Max sold EKSO stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Max Bieschin EKSO stock SEC Form 4 insiders trading

Max has made over 2 trades of the Ekso Bionics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Max bought 10,000 units of EKSO stock worth $11,300 on 7 September 2017.

The largest trade Max's ever made was buying 10,000 units of Ekso Bionics Inc stock on 7 September 2017 worth over $11,300. On average, Max trades about 1,571 units every 43 days since 2015. As of 7 September 2017 Max still owns at least 32,371 units of Ekso Bionics Inc stock.

You can see the complete history of Max Bieschin stock trades at the bottom of the page.

What's Max Bieschin's mailing address?

Max's mailing address filed with the SEC is C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND, CA, 94804.

Insiders trading at Ekso Bionics Inc

Over the last 9 years, insiders at Ekso Bionics Inc have traded over $898,173 worth of Ekso Bionics Inc stock and bought 276,997 units worth $399,153 . The most active insiders traders include Theodore T Wang, Steven Sherman, and Russ Angold. On average, Ekso Bionics Inc executives and independent directors trade stock every 56 days with the average trade being worth of $25,243. The most recent stock trade was executed by Scott G. Davis on 17 August 2023, trading 37,446 units of EKSO stock currently worth $37,446.

What does Ekso Bionics Inc do?

since 2005, ekso bionics has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. the company’s first commercially available product called ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. by designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, ekso bionics is helping people rethink current physical limitations and achieve the remarkable. ekso bionics is headquartered in richmond, california international offices: europe/middle east/africa 29th floor one canada square canary wharf london, united kingdom +44 20 7060 3568 kunden service deutschland +49 89 55067774

Complete history of Max Bieschin stock trades at Ekso Bionics Inc

Ekso Bionics Inc executives and stock owners

Ekso Bionics Inc executives and other stock owners filed with the SEC include:

• Jack Peurach,
  President, Chief Executive Officer, Director
• William R. Shaw,
  Chief Commercial Officer
• John Glenn,
  Chief Financial Officer
• Jack Peurach,
  Pres, CEO & Director
• John F. Glenn,
  CFO & Sec.
• Jason Jones,
  Vice-President of Product Development
• Steven A. Sherman,
  Exec. Chairman
• Steven Sherman,
  Executive Chairman of the Board
• David Carey,
  IR Contact Officer
• William Shaw,
  Chief Commercial Officer
• Stanley Stern,
  Independent Director
• Marilyn Hamilton,
  Independent Director
• Theodore Wang,
  Director
• Thomas Schreck,
  Independent Director
• Charles Li,
  Independent Director
• Jerome Wong,
  Corp. Controller
• Foon Lim Chwee,
  Pres of APAC
• Anthony Pratt,
  US Director of Sales
• Rachael Anderson,
  Global Director of Marketing & Strategic Growth
• Scott G. Davis,
  President & COO
• Theodore T Puissance Cross ...,
  
• Russ Angold,
  President, Ekso Labs
• Tom Looby,
  President & Chief Com. Officer
• Kecheng Li,
  Director
• Russ De Lonzor,
  Vice Pres., Operations
• Max Scheder Bieschin,
  Chief Financial Officer
• Gregory Davault,
  Vice Pres., Global Marketing
• Daniel Boren,
  Director
• Amy Mc Bride Wendell,
  Director
• Howard D Palefsky,
  Director
• Nathan Harding,
  Chief Executive Officer
• Rhonda A. Wallen,
  Director
• Mary Ann Cloyd,
  Director
• Corinna Lathan,
  Director
• Deborah Lafer Scher,
  Director
• Jerome Wong,
  Chief Financial Officer